Artículos del autor

solaci

Antiplatelet

Clnical Practice Dissociated from Study Outcomes: Bad News for Our Patients?

Differences in patient characteristics, changes in treatment algorithms, and advances in device technology, together or separately, might...
solaci -
Pulmonary Valve

Melody: One of the Pioneers in Transcatheter Pulmonary Valve Replacement with Long Term Outcomes

At 10 years of the Melody Investigational Device Exemption we can observe this device for transcatheter pulmonary...
solaci -
Structural heart disease

HYDRA CE | New Models for TAVR Development

The Hydra CE has shown favorable one year efficacy for the new transcatheter aortic valve model, with...
solaci -
Scientific Articles COVID-19

Is the Booster Dose Against COVID-19 Effective for All Ages?

The answer is incontrovertible: it is undeniably effective. For all ages, the confirmed COVID19 and severe case...
solaci -
Scientific Articles COVID-19

Pfizer Booster Dose Efficacy against Omicron

The BNT162b2 vaccine (Pfizer/BioNTech) has previously shown a 95% efficacy against COVID-19. This efficacy has been changing...
solaci -
CHIP LATAM News

CHIP LATAM: SOLACI Opens a New Area with Exceptional Event

We are glad to invite you to the opening of the SOLACI’s Complex Percutaneous Interventions Department (CHIP...
solaci -
Antithrombotic Anticoagulants

Left Atrial Appendage Closure vs Direct Anticoagulants at Long Term

The PRAGUE-17 has shown that left atrial appendage closure is not inferior to direct anticoagulants at long...
solaci -
Valvular Aortic Valve

Minimizing One of Our Major Procedures to a Minimum

In some cases, full atrioventricular (AV) block occurs beyond two days after transcatheter aortic valve replacement (TAVR)....
solaci -